Gain Therapeutics, Inc. (NASDAQ:GANX) Stock Has Average Price Target of $7.50

Key Points

• Analysts hold a “Moderate Buy” consensus on Gain Therapeutics, with five buy ratings and one sell rating. The average 12-month price target is $7.50, including targets of $8.00 from HC Wainwright and $5.00 from BTIG Research.
• Gain Therapeutics shares opened at $1.71, near their 52-week low of $1.53 and well below the 52-week high of $4.34. The company has a market capitalization of approximately $74.6 million and is not currently profitable.
• Institutional investors and hedge funds own 11.97% of the stock, with several firms initiating or increasing positions. In its latest quarter, Gain Therapeutics reported an adjusted loss of $0.11 per share, beating estimates of a $0.14 loss.

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $7.50.

Several research analysts recently commented on the company. Wall Street Zen upgraded Gain Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Sunday, June 21st. HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of Gain Therapeutics in a research report on Monday, August 31st. BTIG Research reaffirmed a "buy" rating and issued a $5.00 target price on shares of Gain Therapeutics in a research report on Tuesday, August 11th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Gain Therapeutics in a report on Friday, September 4th.

Hedge Funds Weigh In On Gain Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Two Sigma Securities LLC acquired a new position in Gain Therapeutics in the 2nd quarter valued at approximately $26,000. HB Wealth Management LLC bought a new position in shares of Gain Therapeutics in the second quarter valued at approximately $26,000. HighTower Advisors LLC bought a new position in Gain Therapeutics in the 2nd quarter worth $35,000. Apollon Wealth Management LLC increased its stake in shares of Gain Therapeutics by 33.7% in the first quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company's stock worth $51,000 after purchasing an additional 6,675 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in shares of Gain Therapeutics during the second quarter worth approximately $277,000. 11.97% of the stock is currently owned by institutional investors and hedge funds.

Gain Therapeutics Stock Performance

Gain Therapeutics stock opened at $1.71 on Friday. The stock has a fifty day moving average of $1.83 and a two-hundred day moving average of $1.85. Gain Therapeutics has a fifty-two week low of $1.53 and a fifty-two week high of $4.34. The company has a market capitalization of $74.62 million, a price-to-earnings ratio of -3.42 and a beta of 0.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.36 and a current ratio of 4.36.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. On average, analysts anticipate that Gain Therapeutics will post -0.5 EPS for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders. The company's research is directed at restoring the function of misfolded or dysfunctional proteins that contribute to disease progression.

Gain Therapeutics uses its proprietary SEE-Tx drug-discovery platform to identify previously unrecognized allosteric binding sites on proteins and develop compounds designed to stabilize or reactivate those proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.